Exempting drugmakers that struck voluntary price deals from the mandatory pricing model undermines the program

CDC and HHS leadership, research integrity, bioethics, regulatory appointments, e-cigarette regulation, and global health funding.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.